Orexo

Uppsala, Sweden - March 28, 2025 – Orexo’s Annual and Sustainability Report for 2024 has been published. It is attached as a PDF to this press release and can be downloaded at https://orexo.com/investors/.

Nikolaj Sørensen, President and CEO, reflects on 2024: Orexo has made significant strides in overcoming challenges and seizing new opportunities. We achieved EBITDA profitability and resolved key legal and financial uncertainties. Continued stabilization in Zubsolv® demand and the advancement of OX640,[1] along with the ongoing development of the AmorphOX® platform, mean we’re positioned well for a promising 2025. With a dedicated team, we are set to embrace new opportunities to deliver our mission to address critical patient needs and drive shareholder value.”

The Annual and Sustainability Report includes:

• Orexo Overview: Insights covering areas such as operations, markets and investment themes, as well as the CEO's comments and the company’s strategic direction.
• Reports: The Board of Directors Report (incl. the Sustainability Report), the Corporate Governance Report, and Financial Reports and Notes.

The Swedish version is also available on the company´s website in European Single Electronic Format (ESEF).

For more information about Orexo, visit www.orexo.com, and stay updated by following us on X and LinkedIn.

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary drug delivery technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm’s main list and is available as ADRs on OTCQX market (ORXOY) in the US.

[1] Rescue medication for allergic reactions, incl. anaphylaxis, with powder-based epinephrine.